InFlectis BioScience Overview

  • Founded
  • 2013

Founded
  • Status
  • Private

  • Employees
  • 10

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $36.5M

  • Investors
  • 7

InFlectis BioScience General Information

Description

Developer of small molecule drugs intended to improve the cellular defense system. The company's drugs identify preclinical-stage development products that modulate key proteins involved in misfolded protein disorders areas through early proof-of-concept, enabling clients to maximize the commercial value of each of its products, improve patient care, and generate significant financial returns for shareholders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 21 rue La Noue Bras de Fer
  • 44200 Nantes
  • France
+33 02 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

InFlectis BioScience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 04-Jan-2021 $36.5M 000.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A) 27-May-2016 00.00 00.000 000.00 Completed Pre-Clinical Trials
2. Seed Round 13-Jan-2015 $2.11M $2.11M Completed Pre-Clinical Trials
1. Grant 01-Jan-2014 $411K Completed Pre-Clinical Trials
To view InFlectis BioScience’s complete valuation and funding history, request access »

InFlectis BioScience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference P3 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Preference P2 0,000 00.000000
Preference P1 40,622 $1.132676
Class O 99,549 $1.132676
To view InFlectis BioScience’s complete cap table history, request access »

InFlectis BioScience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small molecule drugs intended to improve the cellular defense system. The company's drugs identify preclini
Drug Discovery
Nantes, France
10 As of 2022
000.00
0000000000 0 000.00

000000

s aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fug
0000 000000000
Lyon, France
000 As of 0000
00000
00000000 00000

000000

nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa q
0000 000000000
Burlingame, CA
00 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

InFlectis BioScience Competitors (70)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Erytech Pharma Formerly VC-backed Lyon, France 000 00000 00000000 00000
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
0000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
00000000 000000000 Formerly VC-backed Bedford, MA 000 00000 000000000 00000
0000000 Venture Capital-Backed Framingham, MA 00 000.00 00000000000 000.00
You’re viewing 5 of 70 competitors. Get the full list »

InFlectis BioScience Patents

InFlectis BioScience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2016304331-A1 Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent. Active 31-Jul-2015 0000000000
AU-2016304331-B2 Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent. Active 31-Jul-2015 0000000000
CA-2992674-A1 Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent Pending 31-Jul-2015 0000000000
EP-3328369-A1 Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent Pending 31-Jul-2015 0000000000
US-20180221310-A1 Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent Active 31-Jul-2015 A61K31/155
To view InFlectis BioScience’s complete patent history, request access »

InFlectis BioScience Executive Team (5)

Name Title Board Seat Contact Info
Philippe Guedat Ph.D Co-Founder, Chief Executive Officer & Chairman
Philippe Jaffré Chief Financial Officer
Pierre Miniou Ph.D Co-Founder, Chief Operating Officer & Board Member
Beatrice Lejeune Chief Regulatory Officer
Anne Visbecq MD Chief Medical Officer
To view InFlectis BioScience’s complete executive team members history, request access »

InFlectis BioScience Board Members (7)

Name Representing Role Since
Jérôme Guéret GO Capital (France) Board Member 000 0000
Mark Pykett Ph.D Self Board Member 000 0000
Philippe Guedat Ph.D InFlectis BioScience Co-Founder, Chief Executive Officer & Chairman 000 0000
Pierre Miniou Ph.D InFlectis BioScience Co-Founder, Chief Operating Officer & Board Member 000 0000
Taro Inaba Remiges Ventures Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

InFlectis BioScience Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

InFlectis BioScience Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Crédit Mutuel Innovation Venture Capital Minority 000 0000 000000 0
Crédit Mutuel Equity Growth/Expansion Minority 000 0000 000000 0
Remiges Ventures Venture Capital Minority 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
GO Capital (France) Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »